A Prognostic Risk Score for Prostate Cancer Based on PSMA PET-derived Organ-specific Tumor Volumes.

Male Humans Aged Prognosis Positron Emission Tomography Computed Tomography / methods Retrospective Studies Tumor Burden Prostatic Neoplasms / diagnostic imaging Risk Factors Gallium Radioisotopes

Journal

Radiology
ISSN: 1527-1315
Titre abrégé: Radiology
Pays: United States
ID NLM: 0401260

Informations de publication

Date de publication:
05 2023
Historique:
medline: 24 5 2023
pubmed: 19 4 2023
entrez: 18 4 2023
Statut: ppublish

Résumé

Background Prostate-specific membrane antigen (PSMA) PET has high specificity in localizing primary tumors and metastases in patients with prostate cancer, but the individual overall survival probability is still difficult to estimate. Purpose To develop a prognostic risk score using PSMA PET-derived organ-specific total tumor volumes for predicting overall survival in patients with prostate cancer. Materials and Methods Men with prostate cancer who underwent PSMA PET/CT from January 2014 to December 2018 were evaluated retrospectively. All patients from center A were split into training (80%) and internal validation (20%) cohorts. Randomly selected patients from center B were used for external validation. Organ-specific tumor volumes were automatically quantified from PSMA PET scans by a neural network. A prognostic score was selected using multivariable Cox regression guided by the Akaike information criterion (AIC). The final prognostic risk score fitted on the training set was applied to both validation cohorts. Results A total of 1348 men (mean age, 70 years ± 8 [SD]) were included, with 918 patients in the training cohort, 230 in the internal validation cohort, and 200 in the external validation cohort. The median follow-up time was 55.7 months (IQR, 46.7-65.1 months; >4 years; 429 deaths occurred). A body weight-adjusted prognostic risk score integrating total, bone, and visceral tumor volumes obtained high C index values in the internal (0.82) and external (0.74) validation cohorts, as well as in patients with castration-resistant (0.75) and hormone-sensitive (0.68) disease. The fit of the statistical model for the prognostic score was improved compared with a model containing total tumor volume only (AIC, 3324 vs 3351; likelihood ratio test,

Identifiants

DOI: 10.1148/radiol.222010 PMID: 37070991
pubmed: 37070991
doi: 10.1148/radiol.222010
doi:

Substances chimiques

Gallium Radioisotopes 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e222010

Commentaires et corrections

Type : CommentIn

Auteurs

Robert Seifert (R)

From the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).
ORCID: 0000-0001-5985-7701

Sazan Rasul (S)

From the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).
ORCID: 0000-0003-2898-3232

Konstantin Seitzer (K)

From the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).
ORCID: 0000-0002-9109-9004

Maria Eveslage (M)

From the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).
ORCID: 0000-0002-8802-1134

Laya Rahbar Nikoukar (L)

From the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).
ORCID: 0000-0003-3213-8568

Katharina Kessel (K)

From the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).

Michael Schäfers (M)

From the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).
ORCID: 0000-0002-4008-2755

Josef Yu (J)

From the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).
ORCID: 0000-0003-1426-1538

Alexander R Haug (AR)

From the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).
ORCID: 0000-0002-8308-6174

Marcus Hacker (M)

From the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).
ORCID: 0000-0002-4222-4083

Martin Bögemann (M)

From the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).
ORCID: 0000-0002-2569-4446

Lisa Bodei (L)

From the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).

Michael J Morris (MJ)

From the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).

Michael S Hofman (MS)

From the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).
ORCID: 0000-0001-8622-159X

Kambiz Rahbar (K)

From the Departments of Nuclear Medicine (R.S., L.R.N., K.K., M.S., K.R.) and Urology (K.S., M.B.), University Hospital Münster, Albert-Schweitzer-Campus 1, D-48149 Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany (R.S.); German Cancer Consortium (DKTK), Essen, Germany (R.S.); West German Cancer Center, Essen and Münster, Germany (R.S., K.S., L.R.N., K.K., M.S., M.B., K.R.); Department of Nuclear Medicine, University Hospital Vienna, Vienna, Austria (S.R., J.Y., A.R.H., M.H.); Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany (M.E.); Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria (A.R.H.); Department of Nuclear Medicine (L.B.) and Genitourinary Oncology Service (M.J.M.), Memorial Sloan Kettering Cancer Center, New York, NY; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).
ORCID: 0000-0002-4591-4055

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › A Prognostic Risk Score for Prostate Cancer...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › A Prognostic Risk Score for Prostate Cancer...
questionsmedicales.fr › Diagnostic › Pronostic › A Prognostic Risk Score for Prostate Cancer...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Tomographie par émission de positons couplée à la tomodensitométrie › A Prognostic Risk Score for Prostate Cancer...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › A Prognostic Risk Score for Prostate Cancer...
questionsmedicales.fr › Techniques d'investigation › Charge tumorale › A Prognostic Risk Score for Prostate Cancer...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › A Prognostic Risk Score for Prostate Cancer...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Facteurs de risque › A Prognostic Risk Score for Prostate Cancer...
questionsmedicales.fr › Produits chimiques inorganiques › Métaux › Métaux lourds › Gallium › Isotopes du gallium › Radio-isotopes du gallium › A Prognostic Risk Score for Prostate Cancer...